Clone_6
EMCi225-C
General
Cell Line |
|
| hPSCreg name | EMCi225-C |
| Cite as: | EMCi225-C (RRID:CVCL_D0VK) |
| Alternative name(s) |
Clone_6
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
PFIZi028-A (B212c7) Donor's gene variants: C12orf57, DHPS, DHPS Donor diseases: Neurodevelopmental Disorder |
| Last update | 22nd August 2023 |
| Notes | HNRNPC variant NC_000014.9: g.21211238_21211264del |
| User feedback | |
Provider |
|
| Generator |
Erasmus MC (EMC)
Contact:
Erasmus MC (EMC) |
External Databases |
|
| BioSamples | SAMEA114072402 |
| Cellosaurus | CVCL_D0VK |
| Wikidata | Q123031241 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
No |
Donor Information
General Donor Information |
|
| Sex | male |
| Age of donor (at collection) | 15-19 |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Family history | de-novo |
| Is the medical history available upon request? | Yes via treating physician |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Yes
XY,46
Karyotyping method:
Array CGH
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA114093380 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Please provide contact information of the holder of the original Donor Information Sheet. | m.ghazvini@erasmusmc.nl |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | EMC METC |
| Approval number | NL60886.078.17 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
| Source cell type |
1) Reddish in color. 2) relating to erythrocytes or their precursors.
Synonyms
|
| Source cell origin |
1: The fluid that circulates in the heart, arteries, capillaries, and veins of a vertebrate animal carrying nourishment and oxygen to and bringing away waste products from all parts of the body. 2: A comparable fluid of an invertebrate.
Synonyms
|
| Age of donor (at collection) | 15-19 |
| Collected in | 2020 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Is reprogramming vector detectable? |
No |
| Methods used |
RT-PCR
|
| Notes on reprogramming vector detection | ct: N/A |
Vector free reprogramming |
|
Other |
|
| Selection criteria for clones | morphology, marker expression, genotyping |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| O2 Concentration | 20 % |
| CO2 Concentration | 5 % |
| Medium |
Other medium:
Base medium: Stemflex
Main protein source: Albumine Serum concentration: % |
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| SOX2 |
Yes |
|
||||
| SSEA-4 |
Yes |
|
||||
| TRA 1-81 |
Yes |
|
||||
| NANOG |
Yes |
|
|
|||
| POU5F1 (OCT-4) |
Yes |
|
|
|||
| ZFP42 (REX-1) |
Yes |
|
||||
| KLF4 |
Yes |
|
||||
| c-MYC |
Yes |
|
||||
| GDF3 |
Yes |
|
||||
| DPPA5 (ESG1) |
Yes |
|
||||
| FGF4 |
Yes |
|
||||
| TERT |
Yes |
|
Differentiation Potency
In vitro directed differentiation
| Marker | Expressed |
| SOX17 |
Yes |
| FOXA2 |
Yes |
In vitro directed differentiation
| Marker | Expressed |
| KDR |
Yes |
| TBXT (Brachyury) |
Yes |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46,XY
Karyotyping method:
Array CGH
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.